MedTrace Logo

Neurofeedback Intervention for Preclinical Alzheimer's Disease

NCT04300933 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2020-03-09

No results posted yet for this study

Summary

Alzheimer's disease (AD) is the most common form of neurodegenerative disorders leading to dementia. Currently, there has been no effective pharmacologic therapy for this disease. Electroencephalogram-based neurofeedback is considered as a potentially treatment strategy. In this project, the investigators aim to investigate the effectiveness of neurofeedback therapy on cognition for individuals with subjective cognitive decline (SCD). Participants will receive electroencephalogram-based neurofeedback therapy once a day for successive five days. Then, the investigators will evaluate the changes of memory function between baseline and post-therapy visits.

Conditions

  • Alzheimer Disease
  • Subjective Cognitive Decline
  • Neurofeedback
  • Electroencephalogram

Interventions

BEHAVIORAL

Electroencephalogram-based neurofeedback

In this project, SCD participants will receive electroencephalogram-based neurofeedback therapy, once a day, for 5 days. Then, the investigators will compare their memory changes between baseline and post-therapy visits.

Sponsors & Collaborators

  • Beijing Institute of Technology

    collaborator OTHER

  • XuanwuH 2

    lead OTHER

Principal Investigators

  • Ying Han, PhD · Xuanwu Hospital of Capital Medical University

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-01
Primary Completion
2019-08-01
Completion
2019-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04300933 on ClinicalTrials.gov